Bayer considers putting an end to US glyphosate sales

“Removing glyphosate from residential use would be a step in the right direction.”


Bayer announced yesterday it would be willing to consider ending U.S. residential sales of their harmful herbicide, RoundUp. 

This announcement comes after a federal judge rejected a $2 billion class-action proposal from Bayer to avert future lawsuits alleging its popular Roundup herbicide causes cancer, reports Common Dreams.

Bayer claims they “will immediately engage with partners to discuss the future of glyphosate-based products in the U.S. residential market” in a move aimed at “mitigating future litigation risk.” 

As we reported earlier this week, despite a flawed Trump-era review on glyphosate, the harmful key ingredient in Monsanto’s RoundUp,  Biden’s EPA has decided to keep the toxic herbicide on shelves while under review, with no deadline as to when a decision will be made.

Health, environmental, and human rights activists have fought to hold Monsanto and Bayer accountable for the harm RoundUp has caused for years. 

“Removing glyphosate from residential use would be a step in the right direction, as most of the cases now pending settlement involved serious exposure from non-farm uses,” says Ken Cook, president of the Environmental Working Group (EWG). 

Glyphosate-containing products in the U.S. residential market bring in about 300 million euros in annual revenue, reports Sustainable Pulse


If you liked this article, please donate $5 to keep NationofChange online through November.